Regulatory strategy that plans the whole route before the first submission
Regulatory strategy consulting for drugs and devices from a clinician led team serving India, MENA, Europe, and global markets.
The most expensive regulatory mistakes are made early, in the choices nobody revisits: the pathway assumed rather than confirmed, the market sequence driven by commercial hope rather than regulatory logic, the evidence package built for one authority and rejected by the next. Regulatory strategy is the work of making those choices deliberately, with the whole route in view, before resources are committed to any single submission.
EvySaif provides regulatory strategy consulting for pharmaceutical, biotech, and medical device companies planning entry into one market or many. We map the regulatory pathway for the product and its classification, sequence submissions across markets to reuse evidence intelligently, identify the evidence gaps that need closing before filing, and plan the lifecycle so post-approval changes do not become post-approval crises. Strategy connects directly to execution through our regulatory submissions and regulatory writing services.
What regulatory strategy decides
- Pathway and classification. Confirming the regulatory route and product classification in each target market, since a misjudged classification restructures the entire evidence requirement.
- Market sequencing. Ordering submissions so a reference approval strengthens later ones and evidence generated for one market serves the next, rather than filing everywhere at once and everywhere weakly.
- Evidence gap analysis. Identifying, early, where the clinical, non-clinical, or quality package will not satisfy a target authority, while there is still time to address it.
- Lifecycle and change planning. Anticipating variations, renewals, and post-approval commitments so the maintenance burden is designed rather than discovered.
Across established and emerging markets
Regulatory logic differs by region, and the emerging markets are where the differences bite hardest. We plan across ICH regions (US FDA, EMA, PMDA) and the markets whose requirements are formalizing quickly, including India's CDSCO, Saudi Arabia's SFDA, and the UAE authorities, where sequencing and reference-approval strategy materially affect timelines. Our market-specific pages for CDSCO India, SFDA Saudi Arabia, and US FDA describe the execution detail behind the strategy.
What we deliver
Market entry strategy
A regulatory route and evidence plan for each target market, built from the product, its classification, and its data.
Global submission sequencing
A filing sequence that reuses evidence and leverages reference approvals instead of filing everywhere simultaneously.
Evidence gap analysis
Early identification of where the package will not satisfy a target authority, while gaps can still be closed.
Lifecycle strategy
Variation, renewal, and post-approval change planning so maintenance is designed rather than improvised.
Built to the standards that matter
Frequently asked questions
When should regulatory strategy work begin?
As early as possible, ideally before pivotal evidence generation, because the strategy shapes what evidence you need and for which markets. Strategy done after the data exist can only optimize within constraints already set.
Do you cover both drugs and medical devices?
Yes. The strategic questions differ, drug pathways versus device classification and conformity routes, but the discipline is the same, and we plan for both, including combination considerations.
How do you handle emerging markets like the Gulf and India?
We plan sequencing to use reference approvals from established markets where the target authority accepts them, and we build the market-specific requirements (such as SFDA economic evaluation or CDSCO documentation) into the plan rather than discovering them at filing.